Aduro Biotech Scientific Advisor and Co-Founder of Aduro Biotech Europe Wiebe Olijve Honored with Royal Decoration
November 21 2017 - 1:00AM
Aduro Biotech, Inc. (Nasdaq: ADRO), a biopharmaceutical company
with three distinct immunotherapy technologies, today announced
that Wiebe Olijve, PhD, a member of its scientific advisory board
and co-founder of Aduro Biotech Europe (formerly known as
BioNovion), has been named a Knight in the Order of the Netherlands
Lion. This prestigious award was bestowed on Dr Olijve by His
Majesty King Willem-Alexander of the Netherlands for his
outstanding international contribution to the development of
innovative and life-saving medicines. Dr Olijve received the Royal
Decoration from the Mayor of Oss during the Aduro Biotech Europe
Partners in Immuno-Oncology symposium on November 20.
A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/c6babad7-a3f7-4dd3-a456-8cb67821fd1b
“Dr Olijve’s achievements have dramatically improved the health
of countless people in The Netherlands and globally. His pioneering
work in biotechnology was key to creating new classes of drugs and
vaccines based on recombinant DNA technology. More recently, as a
co-founder of BioNovion, he was a key contributor to the
development of innovative antibodies with potential for treating
cancer, including Aduro’s anti-APRIL program, which is expected to
enter clinical studies in 2017,” said Hans van Eenennaam, PhD,
chief operational officer of Aduro Biotech Europe. “We extend our
heartfelt congratulations to Wiebe and are honoured to have him as
a member of our scientific advisory board.”
“On behalf of the city of Oss, I would like to congratulate
Wiebe Olijve with this Decoration, which recognises his great
achievements in drug discovery and development. Not only have his
achievements made a significant impact on the health of so many
people, but the development and manufacturing of products, such as
Puregon and Keytruda, in the Oss area have been and still are an
important source of employment for the city,” said Mayor Wobine
Buijs-Glaudemans.
Achievement in Dr Olijve’s distinguished career include:
- First person to apply recombinant DNA technology in
Netherlands-based pharmaceutical labs, resulting in the production
of the world’s first recombinant DNA-based vaccine (1981).
- Inventor of recombinant follicle-stimulating hormone (Puregon®
(follicle stimulating hormone), which has served the medical need
of many couples who suffer from infertility. Over one million
babies have been born with the help of Puregon.
- Founder of Organon Research Center USA, site of ground breaking
research that lead to the discovery of Keytruda®
(pembrolizumab).
- Co-founder of BioNovion, a company acquired by Aduro Biotech in
2015 for its proprietary B-select antibody technology platform and
pipeline.
To view Dr. Olijve’s bio, please visit the Aduro website at:
http://www.aduro.com/about/scientific-advisory-board.
About Aduro Aduro Biotech, Inc. is an
immunotherapy company focused on the discovery, development and
commercialization of therapies that transform the treatment of
challenging diseases. Aduro's technology platforms, which are
designed to harness the body's natural immune system, are being
investigated in cancer indications and have the potential to expand
into autoimmune and infectious diseases. Aduro's LADD technology
platform is based on proprietary attenuated strains of Listeria
that have been engineered to express tumor-associated antigens to
induce specific and targeted immune responses. This platform is
being developed as a treatment for multiple indications, including
mesothelioma, gastric, ovarian, lung and prostate cancers.
Additionally, a personalized form of LADD, or pLADD, is in Phase 1
development utilizing tumor neoantigens that are specific to an
individual patient’s tumor. Aduro's STING Pathway Activator
platform is designed to activate the STING receptor in immune
cells, resulting in a potent tumor-specific immune response.
ADU-S100 is the first STING Pathway Activator compound to enter the
clinic and is currently being evaluated in both a Phase 1
monotherapy study as well as a Phase 1b combination study with an
anti-PD1 immune checkpoint inhibitor. Aduro’s B-select monoclonal
antibody platform is comprised of a number of immune modulating
assets in research and preclinical development, including
BION-1301, an anti-APRIL antibody. Aduro is collaborating with
leading global pharmaceutical companies to expand its products and
technology platforms. For more information, please visit
www.aduro.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include
statements regarding our intentions or current expectations
concerning, among other things, our technology platforms, plans,
and the potential for eventual regulatory approval of our product
candidates. In some cases, you can identify these statements by
forward-looking words such as “may,” “will,” “continue,”
“anticipate,” “intend,” “could,” “project,” “seek”, “expect” or the
negative or plural of these words or similar expressions.
Forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties that could cause actual
results and events to differ materially from those anticipated,
including, but not limited to, our history of net operating losses
and uncertainty regarding our ability to achieve profitability, our
ability to develop and commercialize our product candidates, our
ability to use and expand our technology platforms to build a
pipeline of product candidates, our ability to obtain and maintain
regulatory approval of our product candidates, our inability to
operate in a competitive industry and compete successfully against
competitors that have greater resources than we do, our reliance on
third parties, and our ability to obtain and adequately protect
intellectual property rights for our product candidates. We
discuss many of these risks in greater detail under the heading
“Risk Factors” contained in our quarterly report on Form 10-Q for
the quarter ended September 30, 2017, which is on file with the
Securities and Exchange Commission. Any forward-looking statements
that we make in this press release speak only as of the date of
this press release. We assume no obligation to update our
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
Contact:Sylvia WheelerSVP, Corporate Affairs510 809 9264 |
|
Media
Contact:Aljanae Reynolds510 809 2452press@aduro.com |
|
|
|
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Apr 2023 to Apr 2024